ACAD10 is not required for metformin's metabolic actions or for maintenance of whole‐body metabolism in C57BL/6J mice

Abstract

AbstractAimAcyl‐coenzyme A dehydrogenase family member 10 (ACAD10) is a mitochondrial protein purported to be involved in the fatty acid oxidation pathway. Metformin is the most prescribed therapy for type 2 diabetes; however, its precise mechanisms of action(s) are still being uncovered. Upregulation of ACAD10 is a requirement for metformin's ability to inhibit growth in cancer cells and extend lifespan in Caenorhabditis elegans. However, it is unknown whether ACAD10 plays a role in metformin's metabolic actions.Materials and MethodsWe assessed the role for ACAD10 on whole‐body metabolism and metformin action by generating ACAD10KO mice on a C57BL/6J background via CRISPR‐Cas9 technology. In‐depth metabolic phenotyping was conducted in both sexes on a normal chow and high fat‐high sucrose diet.ResultsCompared with wildtype mice, we detected no difference in body composition, energy expenditure or glucose tolerance in male or female ACAD10KO mice, on a chow diet or high‐fat, high‐sucrose diet (p ≥ .05). Hepatic mitochondrial function and insulin signalling was not different between genotypes under basal or insulin‐stimulated conditions (p ≥ .05). Glucose excursions following acute administration of metformin before a glucose tolerance test were not different between genotypes nor was body composition or energy expenditure altered after 4 weeks of daily metformin treatment (p ≥ .05). Despite the lack of a metabolic phenotype, liver lipidomic analysis suggests ACAD10 depletion influences the abundance of specific ceramide species containing very long chain fatty acids, while metformin treatment altered clusters of cholesterol ester, plasmalogen, phosphatidylcholine and ceramide species.ConclusionsLoss of ACAD10 does not alter whole‐body metabolism or impact the acute or chronic metabolic actions of metformin in this model.